Chimaeric surrogate light chains (SLC) comprising human VpreB

Patent metadata

Field	Value
Publication number	US-9963716-B2
Application number	US-201414226698-A
Country	US
Kind code	B2
Filing date	Mar 26, 2014
Priority date	Sep 26, 2011
Publication date	May 8, 2018
Grant date	May 8, 2018

Abstract

The present invention relates inter alia to improvements in the production of chimaeric antibodies in non-human transgenic vertebrates such as mice and rats bearing one or more chimaeric antibody transgenes. In particular, the invention provides for improved non-human vertebrates and cells in which VpreB has been species-matched with the variable region of the chimaeric antibodies. Also, embodiments also provide for species-matching of the entire surrogate light chain for efficient pairing with chimaeric heavy chains during B-cell development in vivo in a non-human transgenic vertebrate setting.

First claim

The invention claimed is:

1. A mouse whose genome comprises an antibody heavy chain transgene, the transgene comprising
(a) one or more human VH gene segments, one or more human D gene segments and one or more human JH gene segments operably connected upstream of a constant region gene so that the transgene is capable of undergoing VDJ recombination in vivo to produce an antibody gene comprising a rearranged VDJC encoding an antibody heavy chain having a human variable region and a constant region;

the genome further comprising
(i) a human VpreB gene capable of expressing a human VpreB, and
(ii) a mouse or rat λ5 gene;

wherein the mouse is capable of expressing a chimaeric surrogate light chain comprising human VpreB and mouse or rat λ5 for pairing with the heavy chain.

2. The mouse of claim 1 , wherein the constant region is a mouse constant region.

3. The mouse of claim 1 , wherein the constant region and the λ5 gene are mouse constant region and mouse λ5 gene, respectively.

4. The mouse of claim 2 , wherein the mouse is a strain selected from the group consisting of a 129-derived mouse strain, a C57Bl/6 derived mouse strain and a JM8 derived mouse strain.

5. The mouse of claim 2 , wherein the constant region is of a mouse 129 strain constant region or of a mouse C57Bl/6 strain constant region, and the λ5 gene is a mouse 129 strain or a mouse C57Bl/6 strain.

6. The mouse of claim 1 , wherein said constant region gene and λ5 gene are endogenous genes of said mouse.

7. The mouse of claim 1 , wherein said genome is homozygous for said transgene, human VpreB gene and mouse or rat λ5 gene.

8. The mouse of claim 1 , wherein endogenous antibody heavy chain expression in said mouse is inactive.

9. The mouse of claim 1 , wherein endogenous antibody light chain expression in said mouse is inactive.

10. The mouse of claim 1 , wherein the heavy chain transgene is devoid of a CHI gene segment and the genome comprises no functional antibody light chain locus.

11. The mouse of claim 1 , wherein the heavy chain transgene is devoid of a gamma CHI gene segment and the genome comprises no functional antibody light chain locus.

12. The mouse of claim 1 , wherein the heavy chain transgene is devoid of a mu CHI gene segment and the genome comprises no functional antibody light chain locus.

13. The mouse of claim 1 , wherein said constant region is a mu constant region.

14. The mouse of claim 1 , wherein the human VpreB gene has a nucleotide sequence that is at least 85% identical to SEQ ID NO: 1.

15. The mouse of claim 1 , wherein said genome does not comprise a non-human vertebrate species VpreB1 and/or VpreB2 gene.

16. The mouse of claim 1 , wherein the genome comprises an insertion of human lambda V region or lambda VJ region comprising all of the V regions and intervening sequences, wherein the lambda V region or VJ region comprises a human VpreB gene.

17. The mouse of claim 16 , wherein non-functional V and/or J gene segments are omitted.

18. The mouse of claim 16 , wherein the lambda V region or lambda VJ region comprises a human VpreB gene and its associated human promoter.

19. The mouse of claim 16 , wherein the insertion is an insertion into an antibody light chain locus.

20. The mouse of claim 16 , wherein the insertion replaces endogenous νλ in whole or in part.

21. The mouse of claim 1 , wherein the human VpreB gene is not within the endogenous VpreB-λ5 locus.

22. The mouse of claim 1 , wherein expression of the human VpreB gene is under endogenous control.

23. The mouse of claim 1 , wherein the human VpreB gene is operably linked to one or more DNase I hypersensitive sites.

24. The mouse of claim 1 , wherein the human VpreB gene is present in the genome in 2, 3, 4, 5, 6, 7, 8, 9 or 10 copies.

25. The mouse of claim 1 , wherein all λ5 sequences in the genome are mouse λ5 sequences.

26. The mouse according to claim 22 , wherein the human VpreB gene is operably linked to an endogenous promoter.

27. A mouse according to claim 1 , which expresses a repertoire of Ig heavy chain variable regions that significantly differs from the heavy chain variable region repertoire of a control vertebrate in the proportion as a percentage of use of heavy chain variable gene segments, wherein the control and said mouse genomes are of the same background strain and both comprise said antibody heavy chain transgene, the transgenes being identical in the control and said mouse, and wherein the control does not express a human VpreB.

28. A mouse according to claim 1 , which expresses a repertoire of Ig heavy chain variable regions that significantly differs from the IgH heavy chain variable region repertoire of a control in the proportion expressed as a percentage of use of heavy chain JH gene segments, wherein the control and said mouse genomes are of the same background mouse strain and both comprise said antibody heavy chain transgene, the transgenes being identical in the control and said mouse, and wherein the control does not express a human VpreB.

29. A mouse according to claim 1 , which expresses a repertoire of Ig heavy chain variable regions that significantly differs from the IgH heavy chain variable region repertoire of a control in the proportion expressed as a percentage, of one, more or all heavy chain variable gene segments selected from VH6-1, VH1-3, VH3-7, VH1-8, VH3-9, VH3-11, JH1 and JH6, wherein the control and said mouse genomes are of the same background vertebrate strain and both comprise said antibody heavy chain transgene, the transgenes being identical in the control and said mouse, and wherein the control does not express a human VpreB.

30. The mouse of claim 27 , wherein use of one, more or all of VH6-1, VH1-3, VH3-9 and JH1 is higher in the repertoire of said mouse than in the repertoire of the control.

31. The mouse of claim 27 , wherein use of one, more or all of VH3-7, VH1-8, VH3-11 and JH6 is lower in the repertoire of said mouse than in the repertoire of the control.

32. The mouse of claim 3 , wherein the mouse constant region and said mouse λ5 gene are of the same mouse strain.

33. The mouse of claim 4 , wherein said strain is a C57BL/6-129/Sv hybrid strain.

34. The mouse of claim 13 , wherein said mu constant region is an endogenous mu constant region.

35. The mouse of claim 16 , wherein the genome comprises an insertion of human lambda V region or lambda VJ region comprising all of the V regions and all the J regions, and intervening sequences, wherein the lambda V region or VJ region comprises a human VpreB gene.

36. The mouse of claim 19 , wherein the insertion is an insertion into an endogenous lambda locus upstream of the endogenous lambda constant region.

37. The mouse of claim 26 , wherein said endogenous promoter is an-endogenous VpreB promoter (e.g., a VpreB1 promoter).

38. The mouse of claim 28 , which expresses a repertoire of Ig heavy chain variable regions that differs by a probability of less than 0.05 in a binomial distribution test, from the IgH heavy chain variable region repertoire of a control vertebrate in the proportion expressed as a percentage of use of heavy chain JH gene segments, wherein the control and said mouse geno

Assignees

• Kymab Ltd

Inventors

• Bradley Allan
• Lee E-Chiang
• Liang Qi
• Spensberger Dominik
• England Nicholas

Classifications

• A01K2267/01

  Animal expressing industrially exogenous proteins · CPC title

• A01K2217/07

  Animals genetically altered by homologous recombination · CPC title

• C12N2015/8518

  expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles · CPC title

• A01K2227/105

  Murine · CPC title

• A01K67/0278

  Knock-in vertebrates, e.g. humanised vertebrates · CPC title